Oportuzumab monatox

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Oportuzumab monatox
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized
TargetEpCAM
Clinical data
Trade namesVicinium
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC3072H4723N877O952S12
Molar mass69.6 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Oportuzumab monatox (proposed INN, trade name Vicinium) is an antineoplastic. Chemically, oportuzumab it is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). The drug is produced by Viventia Bio, a Canadian company with laboratories in Winnipeg, Canada and headquarters in Philadelphia, Pennsylvania, USA. Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).[1]

Vicinium has been evaluated in phase I and II clinical trials in patients with non-muscle invasive bladder cancer.[2] In these studies, treatment was associated with clinical benefit.

References[edit]

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. ^ Phase I/II study of vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results D. Fitsialos, S. Seitz, E. Wiecek, M. Rasamoelisolo, J. Entwistle, M. Jewett, G. C. MacDonald and N. Glover. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).

Vol 24, No 18S (June 20 Supplement), 2006: 4580